HomeDRUG • CNSX
add
Bright Minds Biosciences Inc
Previous close
$122.00
Day range
$118.58 - $119.55
Year range
$33.01 - $170.00
Market cap
1.17B CAD
Avg Volume
733.00
P/E ratio
-
Dividend yield
-
Primary exchange
CNSX
Market news
Financials
Income Statement
Revenue
Net income
| (CAD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 6.74M | 325.10% |
Net income | -7.57M | -15,349.58% |
Net profit margin | — | — |
Earnings per share | -0.97 | -9,800.00% |
EBITDA | — | — |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (CAD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 89.05M | 53.80% |
Total assets | 90.88M | 55.62% |
Total liabilities | 1.60M | 179.80% |
Total equity | 89.28M | — |
Shares outstanding | 9.79M | — |
Price to book | 10.64 | — |
Return on assets | -19.23% | — |
Return on capital | -19.65% | — |
Cash Flow
Net change in cash
| (CAD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -7.57M | -15,349.58% |
Cash from operations | -5.82M | -289.18% |
Cash from investing | — | — |
Cash from financing | 13.39M | -74.27% |
Net change in cash | 6.14M | -88.23% |
Free cash flow | -4.01M | -339.54% |
About
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
Founded
2017
Website
Employees
26
